Carmen Criscitiello· @CarmenCriscit · X·· 2 天前评分70
正文 · 原文
Three HER2 ADCs now in HER2-low MBC. At #ESMO26, HORIZON-Breast06 & APEX-Breast01 both beat chemo on PFS (HR ~0.25–0.29). But as @BarbaraPistill2 noted: same payload class as Tdxd, tested vs chemo not the standard. Head-to-head ADC trials needed. #ESMOAmbassadors @myESMO
403 浏览 · 7 赞 · 2 转发 · 0 回复
会议摘要
LBA13按 Proffered paper 1: Breast cancer, early and advanced stage 对上
Trastuzumab rezetecan (SHR-A1811) in HER2-low advanced breast cancer (BC): A randomized, phase 3 study (HORIZON-Breast06)
https://esmocongress.esmo.org来源:Carmen Criscitiello · x.com
